Targeting STAT3 is an efficient strategy for improving the development of novel CML therapeutics for regaining nilotinib response, and re-sensitization of resistant cells could be mediated by induced apoptosis and regulation in energy metabolism. Here, STAT3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.